Prestige Consumer Healthcare Inc. (NYSE:PBH) CEO Ronald M. Lombardi Sells 10,875 Shares

Prestige Consumer Healthcare Inc. (NYSE:PBH) CEO Ronald M. Lombardi sold 10,875 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total transaction of $898,275.00. Following the transaction, the chief executive officer now directly owns 320,952 shares of the company’s stock, valued at $26,510,635.20. This represents a 3.28 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Prestige Consumer Healthcare Stock Performance

PBH traded down $0.03 during mid-day trading on Friday, reaching $84.11. 31,979 shares of the company traded hands, compared to its average volume of 250,648. The company’s fifty day moving average price is $74.13 and its 200-day moving average price is $70.57. The stock has a market capitalization of $4.16 billion, a P/E ratio of 20.46, a P/E/G ratio of 2.32 and a beta of 0.47. The company has a quick ratio of 2.10, a current ratio of 3.56 and a debt-to-equity ratio of 0.61. Prestige Consumer Healthcare Inc. has a 52-week low of $56.61 and a 52-week high of $84.72.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.09. The company had revenue of $283.79 million for the quarter, compared to the consensus estimate of $282.09 million. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. Prestige Consumer Healthcare’s revenue was down .9% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.07 earnings per share. On average, sell-side analysts expect that Prestige Consumer Healthcare Inc. will post 4.45 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. DA Davidson reaffirmed a “buy” rating and set a $95.00 price objective on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $76.00 price target (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. One equities research analyst has rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Prestige Consumer Healthcare currently has a consensus rating of “Moderate Buy” and an average target price of $83.67.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Boston Trust Walden Corp purchased a new position in shares of Prestige Consumer Healthcare in the third quarter worth $41,785,000. Ariel Investments LLC increased its holdings in shares of Prestige Consumer Healthcare by 10.7% in the second quarter. Ariel Investments LLC now owns 2,835,203 shares of the company’s stock worth $195,204,000 after purchasing an additional 274,212 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its position in shares of Prestige Consumer Healthcare by 26.0% in the second quarter. Allspring Global Investments Holdings LLC now owns 1,320,125 shares of the company’s stock worth $90,891,000 after buying an additional 272,773 shares in the last quarter. Victory Capital Management Inc. boosted its stake in Prestige Consumer Healthcare by 9.0% during the second quarter. Victory Capital Management Inc. now owns 2,074,460 shares of the company’s stock valued at $142,827,000 after buying an additional 171,357 shares during the last quarter. Finally, F M Investments LLC purchased a new stake in shares of Prestige Consumer Healthcare during the 2nd quarter worth approximately $11,162,000. Institutional investors own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.